# InQpharm Group clinical trials: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with InQpharm Group as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by InQpharm Group: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/inqpharm-group

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 25, 2019 | NCT03888911 | Benefit and Tolerability of IQP-LU-104 in Weight Loss | InQpharm Group | Not applicable | Completed | Overweight, Obesity | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03888911) |
| July 27, 2017 | NCT03232255 | Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity | InQpharm Group | Not applicable | Completed | Dentin Sensitivity | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03232255) |
| July 24, 2017 | NCT03227276 | Efficacy and Safety of Litramine in 1 Year Weight Loss Study | InQpharm Group | Not applicable | Completed | Obesity; Excess Calories, Overweight and Obesity, Weight Loss | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03227276) |
| April 14, 2017 | NCT03114696 | Benefit of IQP-AO-101 for Sleep | InQpharm Group | Not applicable | Completed | Insomnia, Nonorganic | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03114696) |
| February 20, 2017 | NCT03058367 | Benefit and Tolerability of IQP-AE-103 in Weight Loss | InQpharm Group | Not applicable | Completed | Overweight, Obesity | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03058367) |
| October 12, 2016 | NCT02930681 | Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects | InQpharm Group | Not applicable | Completed | Hyperglycemia, Postprandial | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02930681) |
| October 12, 2016 | NCT02930668 | Efficacy and Safety of Glucosanol™ in Body Weight Reduction | InQpharm Group | Not applicable | Completed | Overweight and Obesity | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02930668) |
| August 22, 2016 | NCT02873910 | Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others | InQpharm Group | Not applicable | Completed | Upper Respiratory Tract Symptoms | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02873910) |
| August 18, 2016 | NCT02871362 | Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol | InQpharm Group | Not applicable | Completed | Blood Pressure, Low Density Lipoprotein Cholesterol Level | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02871362) |
| August 18, 2016 | NCT02871310 | Vasoactive Effects of IQP-AS-118 in Healthy Individuals | InQpharm Group | Not applicable | Withdrawn | Blood Flow, Cardiovascular Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02871310) |
| August 18, 2016 | NCT02871271 | Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness | InQpharm Group | Not applicable | Withdrawn | Fatigue | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02871271) |
| May 17, 2016 | NCT02774486 | Efficacy and Safety of IQP-AK-102 in Reducing Appetite | InQpharm Group | Not applicable | Completed | Appetite Regulation, Appetite Suppression, Energy Intake | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02774486) |
| September 4, 2015 | NCT02541344 | Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects | InQpharm Group | Phase 3 | Completed | Prediabetes, Hyperglycemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02541344) |
| July 2, 2015 | NCT02488356 | Litramine for Weight Loss | InQpharm Group | Not applicable | Completed | Weight Loss | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02488356) |
| January 22, 2014 | NCT02041754 | Safety and Efficacy of IQP-AK-102 in Reducing Appetite | InQpharm Group | Phase 3 | Completed | Weight Loss, Appetite Modulation (Focus of Study) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02041754) |
| October 25, 2013 | NCT01969214 | Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea | InQpharm Group | Not applicable | Completed | Diarrhoea | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01969214) |
| October 17, 2013 | NCT01964885 | Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections | InQpharm Group | Phase 3 | Terminated | Common Cold, Upper Respiratory Tract Infections | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01964885) |
| July 23, 2013 | NCT01905956 | Safety and Efficacy of IQP- AK-102 in Reducing Body Weight | InQpharm Group | Phase 3 | Completed | Weight Loss | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01905956) |
| March 12, 2013 | NCT01809587 | IQP-PO-101 for the Regulation of Bowel Movement Frequency | InQpharm Group | Phase 3 | Completed | Constipation, Irregular Bowel Movement Frequency | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01809587) |
| January 24, 2013 | NCT01774825 | IQP-CL-101 in IBS Management | InQpharm Group | Phase 3 | Completed | Irritable Bowel Syndrome | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01774825) |
| October 31, 2012 | NCT01718639 | Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn | InQpharm Group | Phase 4 | Completed | Postprandial Heartburn | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01718639) |
| September 7, 2012 | NCT01681069 | Efficacy and Safety of IQP-VV-102 in Weight Management | InQpharm Group | Phase 3 | Completed | Obesity, Overweight | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01681069) |
| May 3, 2012 | NCT01590667 | Effect of Litramine on Fat Excretion | InQpharm Group | Phase 4 | Completed | Healthy Subjects | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01590667) |
| January 6, 2012 | NCT01505387 | Litramine in Weight Maintenance | InQpharm Group | Phase 4 | Completed | Weight Maintenance, Overweight, Obese | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01505387) |
| January 4, 2012 | NCT01503957 | Nasya in Allergic Rhinitis | InQpharm Group | Phase 3 | Completed | Allergic Rhinitis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01503957) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 3 | 10 |
| Phase 4 | 5 |
| Not applicable | 14 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Withdrawn | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Overweight | 10 |
| Obesity | 9 |
| Weight Loss | 8 |
| Hyperglycemia | 2 |
| Prediabetic State | 1 |
| Constipation | 1 |
| Cardiovascular Diseases | 1 |
| Dentin Sensitivity | 1 |
| Body Weight | 1 |
| Common Cold | 1 |
| Respiratory Tract Infections | 1 |
| Fatigue | 1 |
| Rhinitis, Allergic | 1 |
| Hypersensitivity | 1 |
| Diarrhea | 1 |
| Irritable Bowel Syndrome | 1 |
| Sleep Initiation and Maintenance Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Wholesale grocers in the United States](https://specstream.ai/data/businesses/wholesale-grocers/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
